Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Sunshine Biopharma Inc. Warrant (SBFMW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: SBFMW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -100% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.96 | 52 Weeks Range 0.05 - 0.98 | Updated Date 05/25/2025 |
52 Weeks Range 0.05 - 0.98 | Updated Date 05/25/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.21 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -13.88% | Operating Margin (TTM) -14.56% |
Management Effectiveness
Return on Assets (TTM) -11.78% | Return on Equity (TTM) -21.17% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 4553895 |
Shares Outstanding - | Shares Floating 4553895 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Sunshine Biopharma Inc. Warrant
Company Overview
History and Background
Sunshine Biopharma Inc. is a pharmaceutical company focused on the research and development of oncology and antiviral drugs. The warrants represent the right to purchase shares of the underlying common stock. The warrants history is intertwined with the financing activities of the company.
Core Business Areas
- Pharmaceutical Development: Sunshine Biopharma focuses on developing novel therapies for cancer and viral infections.
- Research and Development: The company conducts research to identify and develop new drug candidates.
- Drug Commercialization: Once drugs are developed, Sunshine Biopharma aims to commercialize them through partnerships or direct sales.
Leadership and Structure
Sunshine Biopharma's leadership team comprises executives with experience in pharmaceutical development and management. The organizational structure is typical for a small biotech firm, with departments focused on R&D, clinical trials, and business development.
Top Products and Market Share
Key Offerings
- Adva-27a: A potential anti-cancer compound in development. There is no market share data as it is still in development. Competitors would include any company developing therapies for similar cancers.
- Essential 9: Nutraceutical. There is no market share data as it is still generating low revenues. Competitors would include other Nutraceutical companies
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated, with significant investments required for drug development and clinical trials.
Positioning
Sunshine Biopharma is a small player in a large industry, focusing on niche areas within oncology and antiviral therapies. Its competitive advantage, if any, lies in the uniqueness and efficacy of its drug candidates.
Total Addressable Market (TAM)
The TAM for oncology and antiviral drugs is billions of dollars. Sunshine Biopharma's positioning is dependent on the success of their pipeline drugs and the ability to secure funding for development and commercialization.
Upturn SWOT Analysis
Strengths
- Innovative drug candidates
- Experienced research team
- Focus on unmet medical needs
Weaknesses
- Limited financial resources
- Dependence on successful clinical trials
- Small company size
Opportunities
- Partnerships with larger pharmaceutical companies
- Favorable clinical trial results
- Market approval for drug candidates
Threats
- Competition from established pharmaceutical companies
- Failure of clinical trials
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- MRK
- PFE
- JNJ
- GILD
Competitive Landscape
Sunshine Biopharma faces intense competition from large, established pharmaceutical companies with significantly greater resources. Its success hinges on developing unique and effective therapies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited, mainly characterized by R&D progress and fundraising efforts.
Future Projections: Future growth projections are highly speculative and depend on successful drug development and commercialization.
Recent Initiatives: Recent initiatives likely include advancing clinical trials and seeking partnerships.
Summary
Sunshine Biopharma Inc. Warrant is tied to a high-risk, high-reward biopharmaceutical company. The company's potential lies in the success of its drug pipeline, but it faces significant challenges due to limited resources and intense competition. Positive clinical trial results and strategic partnerships are crucial for its future growth. Investors should exercise caution given the speculative nature of the warrants.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings, press releases, financial news sources
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investing in biopharmaceutical companies and their warrants carries significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sunshine Biopharma Inc. Warrant
Exchange NASDAQ | Headquaters Fort Lauderdale, FL, United States | ||
IPO Launch date 2022-02-15 | Chairman, President & CEO Dr. Steve N. Slilaty Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 52 | Website https://sunshinebiopharma.com |
Full time employees 52 | Website https://sunshinebiopharma.com | ||
Sunshine Biopharma, Inc. operates as a pharmaceutical company that focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates through Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products segments. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine The company is based in Fort Lauderdale, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.